NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Jan 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIVACRON (mivacurium chloride) is a short-acting depolarizing neuromuscular blocking agent administered intravenously during anesthesia. It is used to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery and mechanical ventilation. The drug works by binding to acetylcholine receptors at the neuromuscular junction, causing depolarization and temporary paralysis.
LOE Approaching
With LOE approaching and competitive pressure at 30, this is a mature anesthesia product facing market erosion; career growth may be limited to defensive retention strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MIVACRON offers limited career growth due to its mature, LOE-approaching lifecycle and minimal linked job opportunities. This role is best suited for professionals seeking stability in a defensive portfolio position rather than growth and expansion challenges.
Brand ManagerField Sales
Worked on MIVACRON at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.